Devic’s syndrome is also known as neuromyelitis optica which is a central nervous system disorder that specifically affects eye nerves and spinal cord.

The global Devic’s Syndrome (Neuromyelitis Optica) Treatment market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.

The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report aims to provide a comprehensive presentation of the global market for Devic’s Syndrome (Neuromyelitis Optica) Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Devic’s Syndrome (Neuromyelitis Optica) Treatment.

Report Scope

The Devic’s Syndrome (Neuromyelitis Optica) Treatment market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Devic’s Syndrome (Neuromyelitis Optica) Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Devic’s Syndrome (Neuromyelitis Optica) Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Report

Report Metric	Details
Report Name	Devic’s Syndrome (Neuromyelitis Optica) Treatment Market
CAGR	5%
Segment by Type	Eculizumab Methylprednisolone Azathioprine Mycophenolate Mofetil Rituximab
Segment by Application	Hospitals Clinic Others
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Alexion Pharmaceuticals, Inc., Teva Pharmaceuticals, Fresenius Kabi AG, Pharmacia & Upjohn (a subsidary of Pfizer), Lupin Ltd., Sagent Pharmaceuticals, Inc., Zydus Pharmaceuticals, Inc., Sandoz Inc. (Novartis), Alkem Laboratories Ltd., Mylan Pharmaceuticals, Inc., Hoffmann-La Roche/ Chugai Pharmaceutical, MedImmune LLC, RemeGen, Ltd.
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Devic’s Syndrome (Neuromyelitis Optica) Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Devic’s Syndrome (Neuromyelitis Optica) Treatment Market report?

Ans: The main players in the Devic’s Syndrome (Neuromyelitis Optica) Treatment Market are Alexion Pharmaceuticals, Inc., Teva Pharmaceuticals, Fresenius Kabi AG, Pharmacia & Upjohn (a subsidary of Pfizer), Lupin Ltd., Sagent Pharmaceuticals, Inc., Zydus Pharmaceuticals, Inc., Sandoz Inc. (Novartis), Alkem Laboratories Ltd., Mylan Pharmaceuticals, Inc., Hoffmann-La Roche/ Chugai Pharmaceutical, MedImmune LLC, RemeGen, Ltd.

What are the Application segmentation covered in the Devic’s Syndrome (Neuromyelitis Optica) Treatment Market report?

Ans: The Applications covered in the Devic’s Syndrome (Neuromyelitis Optica) Treatment Market report are Hospitals, Clinic, Others

What are the Type segmentation covered in the Devic’s Syndrome (Neuromyelitis Optica) Treatment Market report?

Ans: The Types covered in the Devic’s Syndrome (Neuromyelitis Optica) Treatment Market report are Eculizumab, Methylprednisolone, Azathioprine, Mycophenolate Mofetil, Rituximab

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size Growth Rate by Type: 2019 VS 2023 VS 2030

1.2.2 Eculizumab

1.2.3 Methylprednisolone

1.2.4 Azathioprine

1.2.5 Mycophenolate Mofetil

1.2.6 Rituximab

1.3 Market by Application

1.3.1 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Growth by Application: 2019 VS 2023 VS 2030

1.3.2 Hospitals

1.3.3 Clinic

1.3.4 Others

1.4 Study Objectives

1.5 Years Considered

1.6 Years Considered

2 Global Growth Trends

2.1 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Perspective (2019-2030)

2.2 Devic’s Syndrome (Neuromyelitis Optica) Treatment Growth Trends by Region

2.2.1 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Region: 2019 VS 2023 VS 2030

2.2.2 Devic’s Syndrome (Neuromyelitis Optica) Treatment Historic Market Size by Region (2019-2024)

2.2.3 Devic’s Syndrome (Neuromyelitis Optica) Treatment Forecasted Market Size by Region (2025-2030)

2.3 Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Dynamics

2.3.1 Devic’s Syndrome (Neuromyelitis Optica) Treatment Industry Trends

2.3.2 Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Drivers

2.3.3 Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Challenges

2.3.4 Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Devic’s Syndrome (Neuromyelitis Optica) Treatment Players by Revenue

3.1.1 Global Top Devic’s Syndrome (Neuromyelitis Optica) Treatment Players by Revenue (2019-2024)

3.1.2 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue Market Share by Players (2019-2024)

3.2 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Players Covered: Ranking by Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue

3.4 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Concentration Ratio

3.4.1 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue in 2023

3.5 Devic’s Syndrome (Neuromyelitis Optica) Treatment Key Players Head office and Area Served

3.6 Key Players Devic’s Syndrome (Neuromyelitis Optica) Treatment Product Solution and Service

3.7 Date of Enter into Devic’s Syndrome (Neuromyelitis Optica) Treatment Market

3.8 Mergers & Acquisitions, Expansion Plans

4 Devic’s Syndrome (Neuromyelitis Optica) Treatment Breakdown Data by Type

4.1 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Historic Market Size by Type (2019-2024)

4.2 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Forecasted Market Size by Type (2025-2030)

5 Devic’s Syndrome (Neuromyelitis Optica) Treatment Breakdown Data by Application

5.1 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Historic Market Size by Application (2019-2024)

5.2 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Forecasted Market Size by Application (2025-2030)

6 North America

6.1 North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size (2019-2030)

6.2 North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030

6.3 North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Country (2019-2024)

6.4 North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Country (2025-2030)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size (2019-2030)

7.2 Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030

7.3 Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Country (2019-2024)

7.4 Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Country (2025-2030)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size (2019-2030)

8.2 Asia-Pacific Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Growth Rate by Region: 2019 VS 2023 VS 2030

8.3 Asia-Pacific Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Region (2019-2024)

8.4 Asia-Pacific Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Region (2025-2030)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size (2019-2030)

9.2 Latin America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030

9.3 Latin America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Country (2019-2024)

9.4 Latin America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Country (2025-2030)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size (2019-2030)

10.2 Middle East & Africa Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030

10.3 Middle East & Africa Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Country (2019-2024)

10.4 Middle East & Africa Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Country (2025-2030)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Alexion Pharmaceuticals, Inc.

11.1.1 Alexion Pharmaceuticals, Inc. Company Detail

11.1.2 Alexion Pharmaceuticals, Inc. Business Overview

11.1.3 Alexion Pharmaceuticals, Inc. Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction

11.1.4 Alexion Pharmaceuticals, Inc. Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2019-2024)

11.1.5 Alexion Pharmaceuticals, Inc. Recent Development

11.2 Teva Pharmaceuticals

11.2.1 Teva Pharmaceuticals Company Detail

11.2.2 Teva Pharmaceuticals Business Overview

11.2.3 Teva Pharmaceuticals Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction

11.2.4 Teva Pharmaceuticals Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2019-2024)

11.2.5 Teva Pharmaceuticals Recent Development

11.3 Fresenius Kabi AG

11.3.1 Fresenius Kabi AG Company Detail

11.3.2 Fresenius Kabi AG Business Overview

11.3.3 Fresenius Kabi AG Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction

11.3.4 Fresenius Kabi AG Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2019-2024)

11.3.5 Fresenius Kabi AG Recent Development

11.4 Pharmacia & Upjohn (a subsidary of Pfizer)

11.4.1 Pharmacia & Upjohn (a subsidary of Pfizer) Company Detail

11.4.2 Pharmacia & Upjohn (a subsidary of Pfizer) Business Overview

11.4.3 Pharmacia & Upjohn (a subsidary of Pfizer) Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction

11.4.4 Pharmacia & Upjohn (a subsidary of Pfizer) Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2019-2024)

11.4.5 Pharmacia & Upjohn (a subsidary of Pfizer) Recent Development

11.5 Lupin Ltd.

11.5.1 Lupin Ltd. Company Detail

11.5.2 Lupin Ltd. Business Overview

11.5.3 Lupin Ltd. Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction

11.5.4 Lupin Ltd. Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2019-2024)

11.5.5 Lupin Ltd. Recent Development

11.6 Sagent Pharmaceuticals, Inc.

11.6.1 Sagent Pharmaceuticals, Inc. Company Detail

11.6.2 Sagent Pharmaceuticals, Inc. Business Overview

11.6.3 Sagent Pharmaceuticals, Inc. Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction

11.6.4 Sagent Pharmaceuticals, Inc. Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2019-2024)

11.6.5 Sagent Pharmaceuticals, Inc. Recent Development

11.7 Zydus Pharmaceuticals, Inc.

11.7.1 Zydus Pharmaceuticals, Inc. Company Detail

11.7.2 Zydus Pharmaceuticals, Inc. Business Overview

11.7.3 Zydus Pharmaceuticals, Inc. Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction

11.7.4 Zydus Pharmaceuticals, Inc. Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2019-2024)

11.7.5 Zydus Pharmaceuticals, Inc. Recent Development

11.8 Sandoz Inc. (Novartis)

11.8.1 Sandoz Inc. (Novartis) Company Detail

11.8.2 Sandoz Inc. (Novartis) Business Overview

11.8.3 Sandoz Inc. (Novartis) Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction

11.8.4 Sandoz Inc. (Novartis) Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2019-2024)

11.8.5 Sandoz Inc. (Novartis) Recent Development

11.9 Alkem Laboratories Ltd.

11.9.1 Alkem Laboratories Ltd. Company Detail

11.9.2 Alkem Laboratories Ltd. Business Overview

11.9.3 Alkem Laboratories Ltd. Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction

11.9.4 Alkem Laboratories Ltd. Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2019-2024)

11.9.5 Alkem Laboratories Ltd. Recent Development

11.10 Mylan Pharmaceuticals, Inc.

11.10.1 Mylan Pharmaceuticals, Inc. Company Detail

11.10.2 Mylan Pharmaceuticals, Inc. Business Overview

11.10.3 Mylan Pharmaceuticals, Inc. Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction

11.10.4 Mylan Pharmaceuticals, Inc. Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2019-2024)

11.10.5 Mylan Pharmaceuticals, Inc. Recent Development

11.11 Hoffmann-La Roche/ Chugai Pharmaceutical

11.11.1 Hoffmann-La Roche/ Chugai Pharmaceutical Company Detail

11.11.2 Hoffmann-La Roche/ Chugai Pharmaceutical Business Overview

11.11.3 Hoffmann-La Roche/ Chugai Pharmaceutical Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction

11.11.4 Hoffmann-La Roche/ Chugai Pharmaceutical Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2019-2024)

11.11.5 Hoffmann-La Roche/ Chugai Pharmaceutical Recent Development

11.12 MedImmune LLC

11.12.1 MedImmune LLC Company Detail

11.12.2 MedImmune LLC Business Overview

11.12.3 MedImmune LLC Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction

11.12.4 MedImmune LLC Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2019-2024)

11.12.5 MedImmune LLC Recent Development

11.13 RemeGen, Ltd.

11.13.1 RemeGen, Ltd. Company Detail

11.13.2 RemeGen, Ltd. Business Overview

11.13.3 RemeGen, Ltd. Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction

11.13.4 RemeGen, Ltd. Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2019-2024)

11.13.5 RemeGen, Ltd. Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.2 Data Source

13.2 Disclaimer

13.3 Author Details

FEATURED COMPANIES

Alexion Pharmaceuticals Inc

Teva Pharmaceuticals

Fresenius Kabi AG

Pharmacia & Upjohn (a subsidary of Pfizer)

Lupin Ltd

Sagent Pharmaceuticals, Inc

Zydus Pharmaceuticals, Inc.

Sandoz Inc. (Novartis)

Alkem Laboratories Ltd.

Mylan Pharmaceuticals Inc.

Hoffmann-La Roche/ Chugai Pharmaceutical

MedImmune

RemeGen, Ltd.

List of Tables

Table 1. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030

Table 2. Key Players of Eculizumab

Table 3. Key Players of Methylprednisolone

Table 4. Key Players of Azathioprine

Table 5. Key Players of Mycophenolate Mofetil

Table 6. Key Players of Rituximab

Table 7. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030

Table 8. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Table 9. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Region (2019-2024) & (US$ Million)

Table 10. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share by Region (2019-2024)

Table 11. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Forecasted Market Size by Region (2025-2030) & (US$ Million)

Table 12. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share by Region (2025-2030)

Table 13. Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Trends

Table 14. Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Drivers

Table 15. Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Challenges

Table 16. Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Restraints

Table 17. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue by Players (2019-2024) & (US$ Million)

Table 18. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share by Players (2019-2024)

Table 19. Global Top Devic’s Syndrome (Neuromyelitis Optica) Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment as of 2023)

Table 20. Ranking of Global Top Devic’s Syndrome (Neuromyelitis Optica) Treatment Companies by Revenue (US$ Million) in 2023

Table 21. Global 5 Largest Players Market Share by Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue (CR5 and HHI) & (2019-2024)

Table 22. Key Players Headquarters and Area Served

Table 23. Key Players Devic’s Syndrome (Neuromyelitis Optica) Treatment Product Solution and Service

Table 24. Date of Enter into Devic’s Syndrome (Neuromyelitis Optica) Treatment Market

Table 25. Mergers & Acquisitions, Expansion Plans

Table 26. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2019-2024) & (US$ Million)

Table 27. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue Market Share by Type (2019-2024)

Table 28. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Forecasted Market Size by Type (2025-2030) & (US$ Million)

Table 29. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue Market Share by Type (2025-2030)

Table 30. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2019-2024) & (US$ Million)

Table 31. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue Market Share by Application (2019-2024)

Table 32. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Forecasted Market Size by Application (2025-2030) & (US$ Million)

Table 33. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue Market Share by Application (2025-2030)

Table 34. North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 35. North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Country (2019-2024) & (US$ Million)

Table 36. North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Country (2025-2030) & (US$ Million)

Table 37. Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 38. Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Country (2019-2024) & (US$ Million)

Table 39. Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Country (2025-2030) & (US$ Million)

Table 40. Asia-Pacific Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030

Table 41. Asia-Pacific Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Region (2019-2024) & (US$ Million)

Table 42. Asia-Pacific Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Region (2025-2030) & (US$ Million)

Table 43. Latin America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 44. Latin America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Country (2019-2024) & (US$ Million)

Table 45. Latin America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Country (2025-2030) & (US$ Million)

Table 46. Middle East & Africa Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 47. Middle East & Africa Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Country (2019-2024) & (US$ Million)

Table 48. Middle East & Africa Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Country (2025-2030) & (US$ Million)

Table 49. Alexion Pharmaceuticals, Inc. Company Detail

Table 50. Alexion Pharmaceuticals, Inc. Business Overview

Table 51. Alexion Pharmaceuticals, Inc. Devic’s Syndrome (Neuromyelitis Optica) Treatment Product

Table 52. Alexion Pharmaceuticals, Inc. Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2019-2024) & (US$ Million)

Table 53. Alexion Pharmaceuticals, Inc. Recent Development

Table 54. Teva Pharmaceuticals Company Detail

Table 55. Teva Pharmaceuticals Business Overview

Table 56. Teva Pharmaceuticals Devic’s Syndrome (Neuromyelitis Optica) Treatment Product

Table 57. Teva Pharmaceuticals Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2019-2024) & (US$ Million)

Table 58. Teva Pharmaceuticals Recent Development

Table 59. Fresenius Kabi AG Company Detail

Table 60. Fresenius Kabi AG Business Overview

Table 61. Fresenius Kabi AG Devic’s Syndrome (Neuromyelitis Optica) Treatment Product

Table 62. Fresenius Kabi AG Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2019-2024) & (US$ Million)

Table 63. Fresenius Kabi AG Recent Development

Table 64. Pharmacia & Upjohn (a subsidary of Pfizer) Company Detail

Table 65. Pharmacia & Upjohn (a subsidary of Pfizer) Business Overview

Table 66. Pharmacia & Upjohn (a subsidary of Pfizer) Devic’s Syndrome (Neuromyelitis Optica) Treatment Product

Table 67. Pharmacia & Upjohn (a subsidary of Pfizer) Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2019-2024) & (US$ Million)

Table 68. Pharmacia & Upjohn (a subsidary of Pfizer) Recent Development

Table 69. Lupin Ltd. Company Detail

Table 70. Lupin Ltd. Business Overview

Table 71. Lupin Ltd. Devic’s Syndrome (Neuromyelitis Optica) Treatment Product

Table 72. Lupin Ltd. Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2019-2024) & (US$ Million)

Table 73. Lupin Ltd. Recent Development

Table 74. Sagent Pharmaceuticals, Inc. Company Detail

Table 75. Sagent Pharmaceuticals, Inc. Business Overview

Table 76. Sagent Pharmaceuticals, Inc. Devic’s Syndrome (Neuromyelitis Optica) Treatment Product

Table 77. Sagent Pharmaceuticals, Inc. Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2019-2024) & (US$ Million)

Table 78. Sagent Pharmaceuticals, Inc. Recent Development

Table 79. Zydus Pharmaceuticals, Inc. Company Detail

Table 80. Zydus Pharmaceuticals, Inc. Business Overview

Table 81. Zydus Pharmaceuticals, Inc. Devic’s Syndrome (Neuromyelitis Optica) Treatment Product

Table 82. Zydus Pharmaceuticals, Inc. Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2019-2024) & (US$ Million)

Table 83. Zydus Pharmaceuticals, Inc. Recent Development

Table 84. Sandoz Inc. (Novartis) Company Detail

Table 85. Sandoz Inc. (Novartis) Business Overview

Table 86. Sandoz Inc. (Novartis) Devic’s Syndrome (Neuromyelitis Optica) Treatment Product

Table 87. Sandoz Inc. (Novartis) Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2019-2024) & (US$ Million)

Table 88. Sandoz Inc. (Novartis) Recent Development

Table 89. Alkem Laboratories Ltd. Company Detail

Table 90. Alkem Laboratories Ltd. Business Overview

Table 91. Alkem Laboratories Ltd. Devic’s Syndrome (Neuromyelitis Optica) Treatment Product

Table 92. Alkem Laboratories Ltd. Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2019-2024) & (US$ Million)

Table 93. Alkem Laboratories Ltd. Recent Development

Table 94. Mylan Pharmaceuticals, Inc. Company Detail

Table 95. Mylan Pharmaceuticals, Inc. Business Overview

Table 96. Mylan Pharmaceuticals, Inc. Devic’s Syndrome (Neuromyelitis Optica) Treatment Product

Table 97. Mylan Pharmaceuticals, Inc. Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2019-2024) & (US$ Million)

Table 98. Mylan Pharmaceuticals, Inc. Recent Development

Table 99. Hoffmann-La Roche/ Chugai Pharmaceutical Company Detail

Table 100. Hoffmann-La Roche/ Chugai Pharmaceutical Business Overview

Table 101. Hoffmann-La Roche/ Chugai Pharmaceutical Devic’s Syndrome (Neuromyelitis Optica) Treatment Product

Table 102. Hoffmann-La Roche/ Chugai Pharmaceutical Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2019-2024) & (US$ Million)

Table 103. Hoffmann-La Roche/ Chugai Pharmaceutical Recent Development

Table 104. MedImmune LLC Company Detail

Table 105. MedImmune LLC Business Overview

Table 106. MedImmune LLC Devic’s Syndrome (Neuromyelitis Optica) Treatment Product

Table 107. MedImmune LLC Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2019-2024) & (US$ Million)

Table 108. MedImmune LLC Recent Development

Table 109. RemeGen, Ltd. Company Detail

Table 110. RemeGen, Ltd. Business Overview

Table 111. RemeGen, Ltd. Devic’s Syndrome (Neuromyelitis Optica) Treatment Product

Table 112. RemeGen, Ltd. Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2019-2024) & (US$ Million)

Table 113. RemeGen, Ltd. Recent Development

Table 114. Research Programs/Design for This Report

Table 115. Key Data Information from Secondary Sources

Table 116. Key Data Information from Primary Sources

List of Figures

Figure 1. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size Comparison by Type (2024-2030) & (US$ Million)

Figure 2. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share by Type: 2023 VS 2030

Figure 3. Eculizumab Features

Figure 4. Methylprednisolone Features

Figure 5. Azathioprine Features

Figure 6. Mycophenolate Mofetil Features

Figure 7. Rituximab Features

Figure 8. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size Comparison by Application (2024-2030) & (US$ Million)

Figure 9. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share by Application: 2023 VS 2030

Figure 10. Hospitals Case Studies

Figure 11. Clinic Case Studies

Figure 12. Others Case Studies

Figure 13. Devic’s Syndrome (Neuromyelitis Optica) Treatment Report Years Considered

Figure 14. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size (US$ Million), Year-over-Year: 2019-2030

Figure 15. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size, (US$ Million), 2019 VS 2023 VS 2030

Figure 16. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share by Region: 2023 VS 2030

Figure 17. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share by Players in 2023

Figure 18. Global Top Devic’s Syndrome (Neuromyelitis Optica) Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment as of 2023)

Figure 19. The Top 10 and 5 Players Market Share by Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue in 2023

Figure 20. North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 21. North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share by Country (2019-2030)

Figure 22. United States Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 23. Canada Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 24. Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 25. Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share by Country (2019-2030)

Figure 26. Germany Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 27. France Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 28. U.K. Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 29. Italy Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 30. Russia Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 31. Nordic Countries Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 32. Asia-Pacific Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 33. Asia-Pacific Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share by Region (2019-2030)

Figure 34. China Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 35. Japan Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 36. South Korea Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 37. Southeast Asia Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 38. India Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 39. Australia Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 40. Latin America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 41. Latin America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share by Country (2019-2030)

Figure 42. Mexico Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 43. Brazil Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 44. Middle East & Africa Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 45. Middle East & Africa Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share by Country (2019-2030)

Figure 46. Turkey Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 47. Saudi Arabia Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 48. Alexion Pharmaceuticals, Inc. Revenue Growth Rate in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2019-2024)

Figure 49. Teva Pharmaceuticals Revenue Growth Rate in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2019-2024)

Figure 50. Fresenius Kabi AG Revenue Growth Rate in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2019-2024)

Figure 51. Pharmacia & Upjohn (a subsidary of Pfizer) Revenue Growth Rate in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2019-2024)

Figure 52. Lupin Ltd. Revenue Growth Rate in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2019-2024)

Figure 53. Sagent Pharmaceuticals, Inc. Revenue Growth Rate in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2019-2024)

Figure 54. Zydus Pharmaceuticals, Inc. Revenue Growth Rate in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2019-2024)

Figure 55. Sandoz Inc. (Novartis) Revenue Growth Rate in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2019-2024)

Figure 56. Alkem Laboratories Ltd. Revenue Growth Rate in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2019-2024)

Figure 57. Mylan Pharmaceuticals, Inc. Revenue Growth Rate in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2019-2024)

Figure 58. Hoffmann-La Roche/ Chugai Pharmaceutical Revenue Growth Rate in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2019-2024)

Figure 59. MedImmune LLC Revenue Growth Rate in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2019-2024)

Figure 60. RemeGen, Ltd. Revenue Growth Rate in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2019-2024)

Figure 61. Bottom-up and Top-down Approaches for This Report

Figure 62. Data Triangulation

Figure 63. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions